Reprogrammed apoptotic platelets drive rapid hemostasis through phosphatidylserine and prostaglandin E2 signaling in preclinical models
- 3 June 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (852) , eaea0189
Abstract
Uncontrolled hemorrhage in trauma, surgical, organ-related, and endoscopic settings, particularly in patients receiving antiplatelet therapy, remains difficult to manage clinically. Here, we introduce a high phosphatidylserine (PS)–exposed procoagulant platelet (hPPL) derivative reprogrammed from isolated platelets via calcium ionophore A23187–induced apoptosis, enriched in surface PS and capable of driving rapid hemostasis. Retaining a protein profile akin to resting platelets, hPPLs robustly promoted platelet activation and aggregation in human- and rat-derived plasma and whole blood in vitro and demonstrated superior hemostatic efficacy compared with clinical thrombin and commercial hemostatic materials [microporous polysaccharide hemispheres (MPH) and FIBRILLAR] in murine liver injury and porcine gastric ulcer bleeding models, even under antiplatelet treatment. Mechanistically, hPPLs up-regulated prostaglandin E synthase (PTGES), thereby increasing prostaglandin E2 (PGE 2 ) production and its receptor 3 (EP3)–mediated platelet activation, which reinforced PS-mediated clot formation. Our findings identified an apoptosis-driven PTGES-PGE 2 -EP3 signaling axis that augmented PS-mediated coagulation in murine and porcine hemorrhage models and established the hPPL derivative as a topical hemostatic agent with translational potential for organ-related bleeding and distinct advantages in managing complex endoscopic hemorrhages under both physiological and coagulopathic conditions.Keywords
Funding Information
- National Natural Science Foundation of China (82472141)
- Chinese Academy of Sciences (XDC0290202)
- National Key R&D Program of China Nos (2022YFA1207300)
- CAS Project for Young Scientists in Basic Research (YSBR-036)
- Beijing Natural Science Foundation Economic-Technological Development Area Innovation Joint Fund (L248091)
This publication has 45 references indexed in Scilit:
- A Self‐Assembly Pro‐Coagulant Powder Capable of Rapid Gelling Transformation and Wet Adhesion for the Efficient Control of Non‐Compressible HemorrhageAdvanced Science, 2023
- Tranexamic acid in endoscopic sinus and skull base surgery: A systematic review and meta‐analysisInternational Forum of Allergy & Rhinology, 2023
- A review of treatments for non-compressible torso hemorrhage (NCTH) and internal bleedingBiomaterials, 2022
- Adhesive Hemostatic Hydrogel with Ultrafast Gelation Arrests Acute Upper Gastrointestinal Hemorrhage in PigsAdvanced Functional Materials, 2021
- Endoscopic application of novel, infection‐free, advanced hemostatic material: Its usefulness to upper gastrointestinal oozingDEN Open, 2021
- In situ forming gelatin/hyaluronic acid hydrogel for tissue sealing and hemostasisJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2019
- Biomaterials and Advanced Technologies for Hemostatic Management of BleedingAdvanced Materials, 2017
- The effects of nanomaterials on blood coagulation in hemostasis and thrombosisWIREs Nanomedicine and Nanobiotechnology, 2017
- PolySTAT-modified chitosan gauzes for improved hemostasis in external hemorrhageActa Biomaterialia, 2016
- Natural-orifice transluminal endoscopic surgeryBritish Journal of Surgery, 2015